Tempus AI, Inc. (NASDAQ: TEM) had its "neutral" rating re-affirmed by analysts at Piper Sandler. They now have a $70.00 price target on the stock, up previously from $40.00.
Tempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR®
Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care
Tempus AI, Inc. (NASDAQ: TEM) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $65.00 price target on the stock, up previously from $45.00.
Tempus AI, Inc. (TEM) Q3 2024 Earnings Call Transcript [Seeking Alpha]